AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32563171 — intervention group
Group type: EXPERIMENTAL
Intervention: Perampanel (up to 8 mg/day during double-blind phase, up to 12 mg/day during open-label extension phase)
Number of subjects: 163
Study 32563171 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 163
Study 35914215 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote patient monitoring with health coaching (n=188)
Number of subjects: 375
Study 34183012 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg once daily
Number of subjects: 105
Study 34183012 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study 34014298 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase 3 clinical trials including patients with brain metastases
Number of subjects: 0
Study 34014298 — intervention group
Group type: COMPARATOR
Intervention: Phase 3 clinical trials not including patients with brain metastases
Number of subjects: 0
Study 35045098 — intervention group
Group type: EXPERIMENTAL
Intervention: 12% carbohydrate beverage (250 ml bolus containing 30 g maltodextrin and 30 g sucrose)
Number of subjects: 15
Study 35045098 — intervention group
Group type: EXPERIMENTAL
Intervention: 12% carbohydrate beverage
Number of subjects: 15
Study 35045098 — intervention group
Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 15
Study 34435273 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% of the individual anaerobic threshold (IANS)
Number of subjects: 18
Study 34435273 — intervention group
Group type: EXPERIMENTAL
Intervention: 80% of the IANS
Number of subjects: 18
Study 34435273 — intervention group
Group type: EXPERIMENTAL
Intervention: 80% of the IANS with blood flow restriction (BFR)
Number of subjects: 18
Study 34435273 — intervention group
Group type: COMPARATOR
Intervention: Low-intensity (LI) without BFR
Number of subjects: 18
Study 34435273 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity blood flow restriction (LI-BFR)
Number of subjects: 18
Study 34435273 — intervention group
Group type: EXPERIMENTAL
Intervention: All training interventions
Number of subjects: 18
Study 32964458 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-h educational programme about preeclampsia with self-monitoring of blood pressure and urine protein and routine care
Number of subjects: 113
Study 32964458 — intervention group
Group type: COMPARATOR
Intervention: 2-h educational programme relevant to urinary tract infection and routine care
Number of subjects: 113
Study 34704700 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser
Number of subjects: 28
Study 34704700 — intervention group
Group type: COMPARATOR
Intervention: Traditional scalpel
Number of subjects: 28
Study 34704700 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 28
Study 33041442 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous Abciximab
Number of subjects: 50
Study 33041442 — intervention group
Group type: COMPARATOR
Intervention: Intracoronary saline flush
Number of subjects: 50
Study 33041442 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study 35314635 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized 4-b-value DW-MRI (b = 0/100/600/800 s/mm2)
Number of subjects: 210
Study 35314635 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-b-value ADC calculations (0/600 or 0/800 s/mm2)
Number of subjects: 210
Study 35314635 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternate metrics ADCfast (b ≤ 100 s/mm2), ADCslow (b ≥ 100 s/mm2), and fp
Number of subjects: 210
Study 32907375 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquatic high intensity interval training (10 weeks, twice weekly, consisting of 10 one-minute exercise intervals with one-minute rest, achieving ⩾80% of peak heart rate)
Number of subjects: 17
Study 32907375 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 17
Study 32293519 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced and early mobilisation protocol with fitness tracker-based feedback
Number of subjects: 348
Study 32293519 — intervention group
Group type: COMPARATOR
Intervention: Control group with standard mobilisation according to hospital standards and fitness tracker with blackened screen
Number of subjects: 348
Study 36126505 — intervention group
Group type: EXPERIMENTAL
Intervention: Adhesive application after HF surface treatment
Number of subjects: 120
Study 36126505 — intervention group
Group type: EXPERIMENTAL
Intervention: Adhesive application after MEP surface treatment
Number of subjects: 120
Study 36126505 — intervention group
Group type: EXPERIMENTAL
Intervention: Adhesive application in aged condition (180 days + 25,000 thermal cycles)
Number of subjects: 120
Study 33587824 — intervention group
Group type: EXPERIMENTAL
Intervention: Fitusiran 50 mg
Number of subjects: 17
Study 33587824 — intervention group
Group type: EXPERIMENTAL
Intervention: Fitusiran 80 mg
Number of subjects: 17
Study 32594779 — intervention group
Group type: EXPERIMENTAL
Intervention: AK‐HER2
Number of subjects: 96
Study 32594779 — intervention group
Group type: COMPARATOR
Intervention: trastuzumab
Number of subjects: 96
Study 34607519 — intervention group
Group type: EXPERIMENTAL
Intervention: Pertuzumab injection (5 mg/kg)
Number of subjects: 87
Study 34607519 — intervention group
Group type: COMPARATOR
Intervention: Perjeta® (5 mg/kg)
Number of subjects: 87
Study 33806150 — intervention group
Group type: EXPERIMENTAL
Intervention: Christian Orthodox fasting (OF)
Number of subjects: 43
Study 33806150 — intervention group
Group type: COMPARATOR
Intervention: 16:8 time-restricted eating (TRE)
Number of subjects: 43
Study 32463456 — intervention group
Group type: EXPERIMENTAL
Intervention: Osimertinib, 80 mg daily and Bevacizumab, 15 mg/kg once every 3 weeks
Number of subjects: 49
Study 36443896 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-format multi-component programme based on cognitive behavioural therapy and positive psychology (6 sessions, 10 weeks)
Number of subjects: 64
Study 36443896 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 64
Study 32917417 — intervention group
Group type: EXPERIMENTAL
Intervention: Laminaria digitata (LD)
Number of subjects: 20
Study 32917417 — intervention group
Group type: EXPERIMENTAL
Intervention: Undaria pinnatifida (UP)
Number of subjects: 20
Study 32917417 — intervention group
Group type: COMPARATOR
Intervention: Control meal (pea protein)
Number of subjects: 20
Study 34627213 — intervention group
Group type: EXPERIMENTAL
Intervention: Sandwich principle instructional video
Number of subjects: 51
Study 34627213 — intervention group
Group type: COMPARATOR
Intervention: Normal instructional video
Number of subjects: 51
Study 32812644 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol screening and brief intervention
Number of subjects: 33
Study 35475290 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular diet
Number of subjects: 302
Study 35475290 — intervention group
Group type: COMPARATOR
Intervention: Restricted diet
Number of subjects: 302
Study 34135032 — intervention group
Group type: EXPERIMENTAL
Intervention: Data-enabled clinical trials using electronic healthcare records (EHRs)
Number of subjects: 0
Study 34135032 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitating patient recruitment for postmarketing authorisation trials
Number of subjects: 0
Study 34135032 — intervention group
Group type: EXPERIMENTAL
Intervention: Improving trial design and execution through EHR-based methods
Number of subjects: 0
Study 32583557 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 34
Study 32583557 — intervention group
Group type: COMPARATOR
Intervention: Investigator's choice of therapy (IC)
Number of subjects: 34
Study 33973051 — intervention group
Group type: EXPERIMENTAL
Intervention: Double Balloon Catheter (DBC)
Number of subjects: 420
Study 33973051 — intervention group
Group type: COMPARATOR
Intervention: Prostaglandin Pessary (PGE)
Number of subjects: 420
Study 33761288 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT) - 2 sessions per week for 12 weeks, consisting of 40 minutes of treadmill running/walking including warm-up, high-intensity intervals, and cool-down.
Number of subjects: 140
Study 33761288 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) - no intense exercise during the intervention period.
Number of subjects: 140
Study 33093616 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive group patients with DBP ≤ 70 mmHg (SPRINT trial)
Number of subjects: 0
Study 33093616 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive group patients with DBP ≤ 70 mmHg (ACCORD trial)
Number of subjects: 0
Study 33093616 — intervention group
Group type: EXPERIMENTAL
Intervention: Different SBP/DBP levels (CKD patients in SPRINT trial)
Number of subjects: 0
Study 33542383 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual n-back training (NBG)
Number of subjects: 148
Study 33542383 — intervention group
Group type: EXPERIMENTAL
Intervention: Method of loci training (MPG)
Number of subjects: 148
Study 33542383 — intervention group
Group type: COMPARATOR
Intervention: Blank control group (BCG)
Number of subjects: 148
Study 36050256 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipswich Touch Test (IpTT)
Number of subjects: 8
Study 36050256 — intervention group
Group type: COMPARATOR
Intervention: Standard Monofilament Test (SMT)
Number of subjects: 8
Study 34128810 — intervention group
Group type: EXPERIMENTAL
Intervention: Active conditions (intervention)
Number of subjects: 36
Study 34128810 — intervention group
Group type: COMPARATOR
Intervention: Passive controls (no treatment or waitlist)
Number of subjects: 36
Study 34128810 — intervention group
Group type: EXPERIMENTAL
Intervention: MAR-based multiple imputation or maximum likelihood methods
Number of subjects: 36
Study 34128810 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensitivity analysis approaches (pattern‐mixture model and fixed‐value replacement)
Number of subjects: 36
Study 35404691 — intervention group
Group type: EXPERIMENTAL
Intervention: Superimposed high-frequency jet ventilation (SHFJV)
Number of subjects: 60
Study 35404691 — intervention group
Group type: COMPARATOR
Intervention: Conventional high-frequency jet ventilation (CHFJV)
Number of subjects: 60
Study 32829060 — intervention group
Group type: EXPERIMENTAL
Intervention: Specially processed cereals (SPC)
Number of subjects: 26
Study 32829060 — intervention group
Group type: COMPARATOR
Intervention: Intravenous glycerol and dexamethasone
Number of subjects: 26
Study 36104143 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracapsular microdebrider tonsillectomy
Number of subjects: 200
Study 36104143 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracapsular coblation tonsillectomy
Number of subjects: 200
Study 36104143 — intervention group
Group type: COMPARATOR
Intervention: Extracapsular monopolar tonsillectomy
Number of subjects: 200
Study 36104143 — intervention group
Group type: EXPERIMENTAL
Intervention: All surgical methods
Number of subjects: 200
Study 33629614 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive 'dealing with uncertainty' seminars with statistical lessons and diagnostic reasoning
Number of subjects: 209
Study 33629614 — intervention group
Group type: COMPARATOR
Intervention: Seminars without in-depth diagnostic lessons (control group)
Number of subjects: 209
Study 33629614 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive 'dealing with uncertainty' seminars
Number of subjects: 209
Study 32519972 — intervention group
Group type: EXPERIMENTAL
Intervention: ViSi Mobile (VM)
Number of subjects: 90
Study 32519972 — intervention group
Group type: EXPERIMENTAL
Intervention: HealthPatch (HP)
Number of subjects: 90
Study 32519972 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 90
Study 35675604 — intervention group
Group type: EXPERIMENTAL
Intervention: Relugolix combination therapy (relugolix-CT: relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg)
Number of subjects: 509
Study 35675604 — intervention group
Group type: EXPERIMENTAL
Intervention: Relugolix combination therapy (relugolix-CT)
Number of subjects: 509
Study 35675604 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 509
Study 32572795 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training
Number of subjects: 3
Study 32572795 — intervention group
Group type: EXPERIMENTAL
Intervention: Awareness Through Movement®
Number of subjects: 3
Study 32572795 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual everyday life)
Number of subjects: 3
Study 35916920 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination arm (RE + sorafenib)
Number of subjects: 177
Study 35916920 — intervention group
Group type: COMPARATOR
Intervention: Sorafenib arm
Number of subjects: 177
Study 35258271 — intervention group
Group type: COMPARATOR
Intervention: YMCA submaximal cycle test (YMCAT)
Number of subjects: 47
Study 35258271 — intervention group
Group type: COMPARATOR
Intervention: 6-Minute Walk Test (6MWT)
Number of subjects: 47
Study 32608353 — intervention group
Group type: EXPERIMENTAL
Intervention: REACT plus the resource directory (n=399)
Number of subjects: 800
Study 32608353 — intervention group
Group type: COMPARATOR
Intervention: Resource directory only (n=401)
Number of subjects: 800
Study 33202098 — intervention group
Group type: EXPERIMENTAL
Intervention: light + OLED
Number of subjects: 119
Study 33202098 — intervention group
Group type: EXPERIMENTAL
Intervention: dark + OLED
Number of subjects: 119
Study 33202098 — intervention group
Group type: COMPARATOR
Intervention: light + eINK
Number of subjects: 119
Study 33202098 — intervention group
Group type: COMPARATOR
Intervention: dark + eINK
Number of subjects: 119
Study 36051936 — intervention group
Group type: EXPERIMENTAL
Intervention: CT radiomics and clinical imaging features of the primary tumor
Number of subjects: 195
Study 36051936 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical imaging factors associated with bone metastases
Number of subjects: 195
Study 33993727 — intervention group
Group type: EXPERIMENTAL
Intervention: Text message Nudges
Number of subjects: 400
Study 33993727 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 400
Study 32020756 — intervention group
Group type: EXPERIMENTAL
Intervention: Revascularisation in patients with symptoms and/or acute coronary syndromes
Number of subjects: 0
Study 32020756 — intervention group
Group type: EXPERIMENTAL
Intervention: Revascularisation in asymptomatic patients with stable ischaemic heart disease
Number of subjects: 0
Study 36135935 — intervention group
Group type: EXPERIMENTAL
Intervention: MH‐SR (500 mg/tablet)
Number of subjects: 48
Study 36135935 — intervention group
Group type: COMPARATOR
Intervention: Glucophage®‐XR (500 mg/tablet)
Number of subjects: 48
Study 34805718 — intervention group
Group type: COMPARATOR
Intervention: RT plus placebo (P)
Number of subjects: 48
Study 34805718 — intervention group
Group type: EXPERIMENTAL
Intervention: RT plus investigational agent (A)
Number of subjects: 48
Study 35981832 — intervention group
Group type: EXPERIMENTAL
Intervention: IVUS-guided optimization
Number of subjects: 291
Study 35981832 — intervention group
Group type: COMPARATOR
Intervention: Control (standard of care)
Number of subjects: 291
Study 32639170 — intervention group
Group type: EXPERIMENTAL
Intervention: Challenge-focused program targeted toward high autonomous motivation
Number of subjects: 15
Study 32639170 — intervention group
Group type: COMPARATOR
Intervention: Rewards-focused program targeted toward low autonomous motivation
Number of subjects: 15
Study 32639170 — intervention group
Group type: EXPERIMENTAL
Intervention: Both programs
Number of subjects: 15
Study 32768001 — intervention group
Group type: EXPERIMENTAL
Intervention: ECCO2R therapy for ARDS
Number of subjects: 14
Study 32768001 — intervention group
Group type: EXPERIMENTAL
Intervention: ECCO2R therapy for ae‐COPD
Number of subjects: 14
Study 35987076 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular physiotherapy combined with acupuncture
Number of subjects: 40
Study 35987076 — intervention group
Group type: COMPARATOR
Intervention: Normal group
Number of subjects: 40
Study 33073847 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular coiling
Number of subjects: 1644
Study 33073847 — intervention group
Group type: COMPARATOR
Intervention: Neurosurgical clipping
Number of subjects: 1644
Study 36297029 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirulina supplementation (SP group, n = 20)
Number of subjects: 39
Study 36297029 — intervention group
Group type: COMPARATOR
Intervention: Placebo supplementation (PB group, n = 19)
Number of subjects: 39
Study 36297029 — intervention group
Group type: COMPARATOR
Intervention: Comparison between SP and PB groups
Number of subjects: 39
Study 34967166 — intervention group
Group type: EXPERIMENTAL
Intervention: Longidaza 3000 ME therapy in combination with tamsulosin
Number of subjects: 120
Study 34967166 — intervention group
Group type: COMPARATOR
Intervention: Tamsulosin monotherapy
Number of subjects: 120
Study 34967166 — intervention group
Group type: EXPERIMENTAL
Intervention: Longidaza 3000 ME therapy
Number of subjects: 120
Study 35092722 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus (7.5 mg daily for first 3 days, 5.0 mg daily for days 4 and 5)
Number of subjects: 0
Study 35092722 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 35092722 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 0
Study 33368026 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination viloxazine ER (700 mg) + methylphenidate (36 mg)
Number of subjects: 36
Study 33368026 — intervention group
Group type: COMPARATOR
Intervention: Viloxazine ER (700 mg) alone
Number of subjects: 36
Study 33368026 — intervention group
Group type: COMPARATOR
Intervention: Methylphenidate (36 mg) alone
Number of subjects: 36
Study 33881745 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab after CRT
Number of subjects: 0
Study 33881745 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 32068418 — intervention group
Group type: EXPERIMENTAL
Intervention: Female‐Specific Cognitive Behavioral Therapy (FS‐CBT)
Number of subjects: 99
Study 32068418 — intervention group
Group type: COMPARATOR
Intervention: Gender‐Neutral CBT (GN‐CBT)
Number of subjects: 99
Study 34574642 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (diary reflection intervention)
Number of subjects: 80
Study 34574642 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 80
Study 34261483 — intervention group
Group type: EXPERIMENTAL
Intervention: Low socioeconomic position (SEP)
Number of subjects: 1362
Study 34261483 — intervention group
Group type: EXPERIMENTAL
Intervention: Male sex
Number of subjects: 1362
Study 34261483 — intervention group
Group type: EXPERIMENTAL
Intervention: Ophthalmopathy
Number of subjects: 1362
Study 34261483 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulatory complications
Number of subjects: 1362
Study 34261483 — intervention group
Group type: EXPERIMENTAL
Intervention: Institutional type
Number of subjects: 1362
Study 34261483 — intervention group
Group type: EXPERIMENTAL
Intervention: Old age
Number of subjects: 1362
Study 32027763 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted evidence-based intervention from U.S. for disruptive behavior disorders (DBDs) in Uganda, details on dosage and duration not available.
Number of subjects: 0
Study 32027763 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 32665034 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine infusion (0.6 μg/kg for 10 min after central vein catheterization, followed by 0.4 μg/kg/h until the end of surgery)
Number of subjects: 652
Study 32665034 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline administered at the same rate as dexmedetomidine)
Number of subjects: 652
Study 32665034 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine infusion
Number of subjects: 652
Study 32665034 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 652
Study 35906554 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid-free anesthesia with dexmedetomidine (loading dose 0.6 μg·kg−1 for 10 min, then 0.5 μg·kg−1·h−1 continuous infusion) and sevoflurane plus bilateral paravertebral blockade (0.2 μg·kg−1 dexmedetomidine and 0.5% ropivacaine 15 ml per side)
Number of subjects: 101
Study 35906554 — intervention group
Group type: COMPARATOR
Intervention: Opioid-based anesthesia with remifentanil, sevoflurane, and bilateral paravertebral blockade (0.5% ropivacaine 15 ml per side)
Number of subjects: 101
Study 35906554 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid-free anesthesia
Number of subjects: 101
Study 35906554 — intervention group
Group type: COMPARATOR
Intervention: Opioid-based anesthesia
Number of subjects: 101
Study 33394929 — intervention group
Group type: EXPERIMENTAL
Intervention: Vergence/accommodative therapy
Number of subjects: 12
Study 33394929 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (control group)
Number of subjects: 12
Study 32932395 — intervention group
Group type: EXPERIMENTAL
Intervention: Scleral Lens (SL) worn on one eye for 6 hours
Number of subjects: 26
Study 32932395 — intervention group
Group type: COMPARATOR
Intervention: Control eye (no scleral lens)
Number of subjects: 26
Study 32932395 — intervention group
Group type: EXPERIMENTAL
Intervention: Diaton tonometry
Number of subjects: 26
Study 35998132 — intervention group
Group type: EXPERIMENTAL
Intervention: Training-as-usual plus psychotherapy apprenticeship
Number of subjects: 120
Study 35998132 — intervention group
Group type: COMPARATOR
Intervention: Training-as-usual
Number of subjects: 120
Study 33857750 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 63
Study 33857750 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 34253602 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring by a partner nongovernmental organization for 15 months with results disseminated to local and provincial governments.
Number of subjects: 0
Study 34253602 — intervention group
Group type: COMPARATOR
Intervention: Monitoring by a partner nongovernmental organization for 15 months with results disseminated to the public.
Number of subjects: 0
Study 34202690 — intervention group
Group type: EXPERIMENTAL
Intervention: Home Meal Replacement (HMR)
Number of subjects: 64
Study 34202690 — intervention group
Group type: COMPARATOR
Intervention: Control (regular dietary pattern)
Number of subjects: 64
Study 32645771 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitric Oxide (NO) administration during cardiopulmonary bypass (CPB)
Number of subjects: 24